Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today at 8:00 a.m. ET WILMINGTON, Del. – April 30, 2024 – Incyte (Nasdaq:INCY) today reports 2024 first quarter financial results, and provides a status update on the Company's clinical development portfolio. Exhibit 99.1 FOR IMMEDIATE RELEASE "In the first quarter of 2024, total revenues grew 9% year-over-year driven by patient demand growth in the U.S. for Opzelura® (ruxo ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Incyte (INCY) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on April 30, 2024, might help the stock move higher if these key numbers are better than expectatio ...

It has been about a month since the last earnings report for Incyte (INCY) . Shares have added about 1.8% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Incyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Incyte Q4 Earnings & Revenues Fall Short of Estimates ...

Incyte (INCY) announced new results from a mid-stage study evaluating the efficacy and safety of twice-daily Opzelura (ruxolitinib cream 1.5%) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS), a chronic, debilitating skin condition.The phase II study enrolled 69 adult patients (age ≥ 18 years) diagnosed with Hurley stage 1 or 2 HS who have a total abscess and inflammatory nodule (AN) count of 3 to ≤ 10, with no draining tunnels at screening and baseline visits.Resu ...

The allure of penny stocks is understandable. For literally just a few dollars, you can control hundreds, if not thousands, of shares. And if the stock moves just a nickel or dime higher, you can make a killing that sets you up for life.Unfortunately, that’s not the way most penny stocks work. They are just as likely (if not more) to be pump-and-dump scams as they are real companies trying to make their way. Often they won’t even have a product or service available. They are just a story, typically about wh ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new results from a Phase 2 study evaluating the efficacy and safety of twice-daily ruxolitinib cream 1.5% (Opzelura®) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS). These data were presented as a late-breaking oral presentation (Session: S050 – Late-Breaking Research: Session 2) at the American Academy of Dermatology (AAD) Annual Meeting, held from March 8-12, 2024, in San Diego. The stud ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (INCB54707), an oral JAK1 inhibitor, in adult patients with prurigo nodularis (PN). These data were presented as a late-breaking oral presentation (Session: S050 – Late-Breaking Research: Session 2) at the American Academy of Dermatology (AAD) Annual Meeting, held from March 8-12, 2024, in San Diego. The study met its primary endpoint with a ≥4-point impr ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a group of rare, chronic and progressive blood cancers. Through the use of generative artificial intelligence (AI), the stories and experiences of MPN patients were transformed into unique images to help them show their health care team and their loved ones the significant impact of their MPN sy ...

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. Minjuvi® is indicated in combination with lenalidomide, followed by Minjuvi® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, and who are not el ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. The Prescription Drug User Fee Act (PDUFA) date for the FDA decision is August 28, 2024. The BLA is supported by positive data from the AGAVE-201 trial ...